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Background: Hypoxia is a common feature of solid tumors, including HCC. And hypoxia has been reported to
play an important role in HCC progression. However, the potential mechanism of miRNAs in hypoxia mediating
HCC progression still remains unclear.
Methods: The HCC cells were cultured in the atmosphere of 1 % oxygen to induce hypoxia. The microRNA microarray
was employed to search for the hypoxia-inducible miRNAs. RT-PCR, western blot and immunohistochemistry were used
to detect the RNA and protein levels. HUVEC were applied to explore the angiogenesis level.
Results: We found that miR-182 was upregulated in the hypoxia-based microarray. We then revealed that miR-182
was also significantly increased in the HCC tissues compared to the corresponding normal tissues. In vitro capilliary
tube formation assays showed that the miR-182 promoted angiogenesis. RASA1 was demonstrated as the direct target
of miR-182. In addition, the suppression of RASA1 phenocopied the pro-angiogenesis effects of miR-182. Besides, RASA1
was also decreased in the hypoxia HCC cells while the inhibition of miR-182 partially restored the level of RASA1.
Conclusions: Our data showed that hypoxia regulated the expression of miR-182 and RASA1 to promote HCC
angiogenesis.
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Hepatocellular carcinoma (HCC) is one of the most
common cancers, which lead to the third leading cause
of death from cancer worldwide [1]. HCC shares the
common character of tissue hypoxia with other solid
tumors, due to the quick growth of tumor and relatively
low density of microvessels. Upon hypoxic environment,
HCC cells will subsequently lead to elevated angiogenesis
and tumor metastasis, which is resistant to chemotherapy
and cause the poor survival of HCC patients [2–4]. So
investigation of hypoxia-induced molecules will help to
develop new tools for the treatment of HCC.* Correspondence: drwujian@hotmail.com; shusenzheng@zju.edu.cn
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(http://creativecommons.org/publicdomain/zeMicroRNAs (miRNAs) are a class of highly conserved
short RNAs of 21–23 nucleotides that negatively regulate
protein expression via binding to the 3’untranslated region
(3’UTR) of their targeted mRNAs [5, 6]. MiRNAs have
been reported to play an important role in tumor progres-
sion, including apoptosis, proliferation, angiogenesis and
metastasis [7–9]. To date, several miRNAs are identified
to be regulated under hypoxic conditions and are recog-
nized as hypoxic responsive miRNAs, which contribute to
the tumor progression. For example miR-210, which is
overexpressed in HCC, has been reported to be induced
in hypoxic HCC cells and promote the metastasis of HCC
by targeting VMP1 [10]. In addition, Lan J et al. reported
that miR-497 is increased in hypoxic glioma cells and
decreases their sensitivity to TMZ by inhibiting apoptosis
[11]. MiR-182 has been reported to act as a tumor
promoter in several cancer types [12, 13]. A previous study
has demonstrated that miR-182 promotes metastasis indistributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in
operly credited. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Primer sequences for RT-PCR
Name Sense strand Anti-sense strand
GAPDH GTCTCCTCTGACTTCAACAGCG ACCACCCTGTTGCTGTAGCCAA
RASA1 GGGACATCCAATAAACGCCTTCG TTTGCTACTTGGACACTATTCAGG
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hypoxia still remains unclear.
In this study, we identified miR-182 as the hypoxia
responsive miRNA by microRNA microarray analysis.
Then we found that miR-182 was up-regulated in
HCC tissues. In addition, we demonstrated that miR-182
promoted angiogenesis of HCC by targeting RASA1. Our
results indicate that miR-182 promotes the adaptation
of HCC under hypoxic conditions and might acts as
a therapeutic target for HCC.
Materials and methods
Patients and tissue specimens
HCC tissues and their corresponding normal liver tissues
were obtained from 36 HCC patients who underwent
resection of HCC at the First Affiliated Hospital Zhejiang
University School of Medicine, China. All tissue sam-
ples were freshly frozen by liquid nitrogen and stored
at - 80 °C. All the specimens were obtained with informed
consent and approved by the Ethics Committee of
Zhejiang University.
Cell lines and culture
Liver cancer cell lines SK-HEP-1 and HCC-LM3 cells
were purchased from the Shanghai Institute of Cell Biology
(Shanghai, China). The two cell lines were maintained in
the Dulbecco’s modified Eagle medium with 10 % fetal
bovine serum and in the atmosphere at 37 °C containing
5 % CO2. To induce hypoxia, cells were cultured in
the atmosphere of 1 % O2, 5 % CO2 and 94 % N2.
Preparation of tumor cell-conditioned medium (TCM)
HCC cells were transfected for 48 h and then the super-
natant medium was replaced by serum free medium. After
incubation for another 24 h, the medium was collected
following by centrifuging for 10 min at 5000 g and stored
at −80 °C until used.
Human umbilical vein endothelial cells (HUVECs) and
capillary tube formation assay
The HUVECs were obtained from Allcells (Shanghai,
China allcells.biomart.cn) and maintained with Serum
Free Medium for Endothelial Cells (SFM, Invitrogen)
supplemented with 20 % FBS, 0.1 mg/mL of heparin and
0.03 mg/mL of endothelial cell growth supplement.
Primary HUVECs were used at passages 2–7 in all
experiments. For capillary tube formation assay, HUVECs
were transferred to matrigel-coated 96-well plates by
75 % TCM at the density of 2 × 104/well. After incu-
bation for 6 h, capillary-like structures of HUVECs
were photographed under an inverted microscope.
The branch points of the formed tubes, which represent
the degree of angiogenesis in vitro, were scanned and
quantitated at the 100× magnification.RNA oligoribonucleotides and transfection
MiR-182 mimics (MSY0000259), inhibitors (MIN0000259),
si-RASA1 (SI00045360) and AllStars negative control
siRNA (SI03650318) were synthesized by Qiagen
(Germany). The transfection was conducted using li-
pofectamine 2000 (Invitrogen) according to manufac-
turer’s construction.
Luciferase reporter assay
SK-HEP-1 and HCC-LM3 cells were seeded in 24-well
plates and then the cells were co-transfected with miR-182,
anti-miR-182 or control and 100 ng either wild-type or
mutant-type 3’UTR of RASA1 firefly luciferase reporter
plasmid. After incubation for 48 h, firefly and renilla lucif-
erase activities were measured by a dual-luciferase reporter
assay (promega, E2920).
RT-PCR, western blot and immunohistochemistry (IHC)
The regents used and the detailed procedures of RT-PCR,
western blot and IHC were performed as before [7]. For
RT-PCR, GAPDH and U6 were used as the internal
control. The primers of GAPDH, RASA1 were listed
in Table 1 and the primers of U6 (MS00033740) and
miR-182 (MS00008855) were bought from Qiagen. For
western blot, β-actin (A5441, Sigma-Aldrich, 1:2000) was
used as the internal control. Other primary antibodies
used were Hif-1a (ab113642, abcam, 1:1000), RASA1
(ab40677, abcam, 1:1000).
For evaluation of staining score of RASA1 (ab40677,
abcam, 1:50), we applied modified Histo-score (H-score)
method, which in brief was a semi-quantitative assessment
of both fraction of positive cells (0–1) and intensity of
staining (no 0, weak 1, moderate 2, or strong 3). The
H-scores ranged from 0 to 3, which were obtained by
multiplying the fraction and intensity scores.
MiRNA microarray analysis
Agilent oligonucleotide technology was applied to profile
the differentially expressed miRNAs between normoxia
and hypoxia (8 h) groups. In brief, the RNA was isolated
by mirVanaTM miRNA Isolation Kit (Cat#AM1560,
Ambion, Austin, TX, US) and followed by labeling and
hybridization with miRNA Complete Labeling and Hyb
Kit (Cat#5190-0456, Agilent technologies, Santa Clara,
CA, US). The microarray used for hybridization was
Agilent human miRNA (8*60 K) V18.0. Then slides were
scanned by Agilent Microarray Scanner (Cat#G2565BA,
Agilent technologies, Santa Clara, CA, US) and Feature
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CA, US) with default settings. Raw data were normalized
by Quantile algorithm, Gene Spring Software 11.0.
The microarray data was submitted to GEO database
and the GEO accession number was GSE68593.
Statistical analysis
The results are presented as the mean ± standard error
of the mean (SEM). The data of miR-182 and RASA1
expression between groups were subjected to the
Student t test (two-tailed). Mann–Whitney test was
used to compare the difference between two groups.
And for three groups, One-way ANOVA followed by
Tukeys post-hoc test was applied. Fisher exact test
was perform to examine the relationship between
miR-182 expression and clinicopathological characteris-
tics. Statistical analysis was performed with SPSS 15.0 and
GraphPad Prism 5.0. P < 0.05 was considered statistically
significant.
Results
Hypoxia induces the level of miR-182 in HCC cells
Firstly, we applied SK-HEP-1 cells under hypoxia condi-
tions for several time points. We then examined theFig. 1 The expression of miR-182 was enhanced in the hypoxia HCC cells.
time (0 h, 2 h, 8 h, 24 h). b We applied the normoxia SK-HEP-1 cells and hy
hierarchical clustering analysis showed a significant increase of miR-182 in the
normoxia for 8 h. The relative level of miR-182 was detected by RT-PCR. The ehypoxia marker, hypoxia-inducible factor 1 alpha (Hif-1a),
in each group. Western blot results showed that the
Hif-1a level was significantly increased in the 2 h and
8 h time points, and decreased in the 24 h time point
(Fig. 1a). To search for the hypoxia-inducible miRNAs, we
performed microRNA microarray scanning of SK-HEP-1
cells subject to normoxia and hypoxia for 8 h. Among all
the miRNAs profiled, we identified that miR-182 was the
highly induced microRNA in the hypoxia group by setting
the fold change > 2 and p value < 0.01 as the cut-off point
(Fig. 1b).
To validate the microarray data, we then performed
RT-PCR of miR-182 in SK-HEP-1 cells under normoxic
and hypoxic conditions. We found that the expression of
miR-182 was significantly increased under hypoxia
(Fig. 1c). In addition, the miR-182 level was decreased
after the HCC cells were restored in the normoxic condi-
tion for 24 h (Fig. 1c). Therefore, the data suggests that
hypoxia could increase the expression of miR-182.
MiR-182 is significantly increased in HCC tissues and
promotes angiogenesis in HCC
We then explored the expression of miR-182 in 36 pairs
of HCC tissues. Consistent with a previous study [14],a The level of hif-1a in SK-HEP-1 under different hypoxia exposure
poxia SK-HEP-1 cells (8 h) for microRNA microarray. The unsupervised
hypoxia group. c HCC cells were restored to normoxia after applied to
xperiments were performed in three independent times. (**P < 0.01)
Fig. 2 The level of miR-182 was increased in HCC tissues and promotes angiogenesis. a The level of MiR-182 was examined by RT-PCR in 36 pairs
of HCC tissues and their corresponding normal tissues. b The percent of up-regulation of miR-182 in HCC was shown. c Capillary tube formation
assays of HUVECs were performed by using 75 % TCM derived from SK-HEP-1 and HCC-LM3 cells treated with miR-182 mimics or NC or anti-miR-182.
The relative images were shown at the 100× magnification and the results are representative of three independent experiments. (*P < 0.05, **P < 0.01)
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tumor tissues compared to the corresponding normal
tissues (Fig. 2a, b). We then examined the clinicopathologic
significance of miR-182 in HCC by choosing the median of
miR-182 as the cut-off point to separate the low-miR-182
group and the high-miR-182 group (Table 2). We found
that the upregulation of miR-182 was more frequently
observed in the patients with big tumor size (P = 0.018)
and portal vein invasion (P = 0.027). However no signifi-
cant correlation was found between miR-182 and other
clinicopathologic data, including age, gender tumor
number, TNM staging, grade and AFP level.
As hypoxia is an important factor to induce angiogenesis
[15, 16], we predicted that hypoxic-induced miR-182 could
also increase the angiogenesis level. We then performedin vitro capillary tube formation assay in SK-HEP-1 and
HCC-LM3 cells, we found that TCM from the miR-182
group displayed more ability to promote the forma-
tion of capillary-like structures than the NC group,
while the anti-miR-182 group decreased the level of
capillary-like structures (Fig. 2c). These data indicate
that miR-182 is overexpressed in HCC tumors and
could increase the angiogenesis of HCC.
RASA1 is the direct target of miR-182 and inhibits
angiogenesis
It is well reported that the functions of miRNAs are me-
diated by their target genes. So we applied the database
TargetScan and miRanda to search for the potential tar-
get genes of miR-182. Among the predicted genes, we
Table 2 The relationship between miR-182 expression and
clinicopathological characteristics in human HCC patients
Variables All patients miR-182 expression P value
(n = 36) lowa higha
Age (years)
≤55 12 7 5 0.725
>55 24 11 13
Gender
Male 28 13 15 0.691
Female 8 5 3
Size of tumor (cm)
≤5 16 12 4 0.018*
>5 20 6 14
Number of tumor
Single 20 12 9 0.5
Multiple 16 6 9
Portal vein invasion
Negative 25 16 9 0.027*
Positive 11 2 9
TNM staging
I, II 21 13 8 0.176
III 15 5 10
Grade
Well + Moderate 27 15 12 0.09
Poor 9 3 6
AFP (ng/ml)
≤400 10 6 4 0.711
>400 26 12 14
For analysis of correlation between miR-182 expression and clinical features,
fisher exact tests were used. Results were considered statistically significant at
P <0 .05 *
aThe median expression level was used as the cut-off. Low expression of
miR-182 in 18 patients was classified as values below the 50th percentile.
High miR-182 expression in 18 patients was classified as values above the
50th percentile
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both databases (Fig. 3a), but also it has been reported to
correlate with angiogenesis in a previous study [17]. The
dual luciferase reporter results in SK-HEP-1 cells showed
that the transfection of miR-182 mimics exerted repressive
effects of luciferase activity of RASA1 3’UTR plasmid
while the inhibition of miR-182 increased the luciferase
activity (Fig. 3b). Moreover, the RT-PCR and western
blot results in HCC cells lines indicated that overex-
pression of miR-182 reduced the mRNA level and
protein level of RASA1 while the suppression of miR-182
revealed an opposite result (Fig. 3c and Additional file 1:
Figure S1A). Based on the correlation in HCC cells, we
then explore the level of RASA1 and the relationship be-
tween miR-182 and RASA1 in 36 HCC tissues. As shownin Fig. 3d and Additional file 1: Figure S1B, the expression
of RASA1 was reduced in HCC tissues and the tissues
with higher miR-182 levels tended to have the lower ex-
pression of RASA1. Furthermore, TCM from si-RASA1
group promoted the formation of capillary-like structure
(Fig. 3e), which was consistent with miR-182 mimics trans-
fection. Collectively, these findings imply that RASA1 is a
direct target of miR-182 in both HCC cells and tissues.
RASA1 is repressed by hypoxia and miR-182 mediates
hypoxia-reduced RASA1 level
To further determine the relationship between miR-182
and RASA1 under hypoxic conditions, we first explored
the effects of hypoxia on RASA1. The results demon-
strated that the mRNA and protein expression of RASA1
in HCC cells was significantly decreased when exposed to
hypoxia (Fig. 4a). In addition, the RASA1 levels were
significantly increased after the cells were restored to
normoxic conditions (Fig. 4a). Given that RASA1 was the
target of miR-182, we hypothesized that miR-182 might
play a role in regulating hypoxia-reduced RASA1. To test
this hypothesis, we transfected the SK-HEP-1 cells with
miR-182 inhibitors. We found that the inhibition of
miR-182 hindered the suppression effects of hypoxia on
RASA1 expression (Fig. 4b). In conclusion, these results
indicate that the reduction of RASA1 is mediated by up-
regulation of miR-182 under hypoxic conditions.
Conclusion
Increasing studies have proven that hypoxia is involved
in promoting tumor progression and resistance to
therapy [18]. In HCC, hypoxia has been reported to
closely related to the proliferation, metastasis, angiogen-
esis and the outcome of patients [19–21]. Therefore,
searching for novel hypoxia related markers might have
potentially important clinical applications. A previous
report has shown that the hypoxia-inducible miRNA,
miR-210, augments the metastatic potential of HCC
by targeting VMP1 [10]. Here, we sought to identify new
hypoxia-induced miRNAs of HCC through microRNA
microarray of hypoxic group and normoxic group in
SK-HEP-1 cells. We selected the time point of 8 h,
because the level of Hif-1a, which is the vital marker
of hypoxia, was relatively higher than other groups.
Among the differential miRNAs, miR-182 is a remarkable
one with the fold change > 2 and P value < 0.01. Further-
more, upon restored to the normoxic conditions, the level
of miR-182 significantly decreased. Till now, this is the
first attempt to illuminate the dynamic change of miR-182
under hypoxia.
The importance of miR-182 in cancer has been re-
ported in several studies. Previous researches have
shown that miR-182 is up-regulated in prostate cancers
[22], colorectal cancers [23]. Similarly, here we found
Fig. 3 (See legend on next page.)
Du et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:67 Page 6 of 9
(See figure on previous page.)
Fig. 3 RASA1 was the direct target of miR-182 and the inhibition of RASA1 promoted angiogenesis. a miR-182 and its predicted binding
sequence in the 3’UTR of RASA1. The mutant sequence was constructed by changing their complementary sites. b The SK-HEP-1 cells were
co-transfected with miR-182 mimics or inhibitors or NC and 100 ng firefly luciferase reporter plasmid containing wild-type or mutant type 3’UTR
of RASA1. After incubation for 48 h, the firefly luciferase activity of each sample was detected and normalized to the renilla luciferase activity. The
data represent the mean ± SEM of triplicates. c The protein levels of RASA1 were examined by western blot after transfected with miR-182 mimics
or inhibitors. d IHC assays were applied to explore the protein levels of RASA1 in 36 HCC tissues. The representative images were shown at the
400× magnification. The medium level of all 36 cases was chosen as the cut-off point for separating low-miR-182 (n = 18) and high-miR-182
(n = 18) groups. e Capillary tube formation assays was used to detect the angiogenesis effects of RASA1 suppression. The data represent the
mean ± SEM of triplicates. (*P < 0.05, **P < 0.01)
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sues. Analysis between clinicopathological features and
miR-182 expression revealed that the increase of miR-182
was significantly correlated with tumor size and portal
invasion. These findings together indicate that miR-182
may acts as a valuable oncogene in HCC and further
functional mechanism of miR-182 need to be explored to
support its significance. A previous study in HCC reported
that miR-182 regulates the metastasis activity by targetingFig. 4 The level of RASA1 was reduced under hypoxia conditions and part
protein levels of RASA1 in SK-HEP-1 cells under normoxia or hypoxia or res
b SK-HEP-1 cells were transfected with miR-182 inhibitor or negative contr
were detected. a-b The results indicate triplicates. (**P < 0.01)MSPP1 [14]. But the potential role of miR-182 in other
pathological progressions, such as angiogenesis, remains
unclear.
Angiogenesis is vital for tumor growth and metastasis,
which will accelerate the death of patients with cancer
[24, 25]. Hence, identifying anti-angiogenesis targets is
thought to be effective in treating cancers. Recently
emerging studies have reported angiogenesis-related
markers in HCC [26–28]. In the present study, we firstly restored while transfected with anti-miR-182. a The mRNA and
tored to normoxia were detected by RT-PCR and western blot.
ol in normoxic or hypoxic conditions. The mRNA and protein levels
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applying HUVEC. Hypoxia is thought to be an important
factor to promote angiogenesis, mainly by up-regulating
VEGFA [29, 30]. Our results highlight another important
molecule induced under hypoxia, which promotes angio-
genesis, and might enhance the malignancy of tumors.
Furthermore, during the investigation of the mechan-
ism of miR-182 in HCC progression, we discovered
that RASA1 was the direct target of miR-182 by the
following evidence: miR-182 level and RASA1 expres-
sion are inversely correlated in both HCC cells and
tissues; miR-182 directly binds to the 3’UTR regions of
RASA1. RASA1, acting as the suppressor of RAS func-
tions, is involved in the tumorigenicity of colorectal cancer
[31] and gastric cancer [32]. Another research has re-
vealed that loss of RASA1 promotes endothelium patho-
logical angiogenesis [17]. Here we found that silencing of
RASA1 could mimic the effects of miR-182 overexpression
on angiogenesis. These results indicate that the increase
of miR-182 promotes angiogenesis via down-regulating
RASA1 in HCC.
In conclusion, we identified that miR-182 was induced
in HCC cells under hypoxia and promoted angiogen-
esis by targeting RASA1. These findings facilitate our
understanding of hypoxia related markers in HCC
and the hypoxia/miR-182/RASA1 pathway might serve as
a promising strategy for HCC therapy.
Additional file
Additional file 1: Figure S1. The mRNA level of RASA1 in HCC cells
transfected with miR-182 mimics or inhibitors and in HCC tissues. (A)
miR-182 mimics increased while miR-182 inhibitors decreased the mRNA
level of RASA1 in SK-HEP-1 cells. (B) The mRNA level of RASA1 were
detected by RT-PCR in 36 HCC tissues. Compared to the non-tumor
group, the tumor group showed a less level of RASA1.
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